瑞士公司Molecular Partners周四表示，将裁减近半数员工，以收窄业务重心，聚焦蓬勃发展的放射治疗药物领域。
Switzerland's Molecular Partners is cutting its workforce nearly in half, it said on Thursday, as it aims to narrow its focus on the booming field of radiotherapeutic medicines.
这家临床阶段生物技术公司已与制药巨头诺华（NOVN.S）和美国艾伯维（ABBV.N）建立合作，此次将把员工人数削减至多44%，即最多55人。
The clinical-stage biotech company, which has partnered with pharma giant Novartis (NOVN.S) and American AbbVie (ABBV.N), is set to reduce its employee headcount by up to 44%, or up to 55 people.
首席执行官帕特里克·阿姆斯图茨在一份声明中表示，其主要放射治疗候选药物新出现的临床数据促使公司转型，聚焦靶向放射治疗。Molecular Partners表示，裁员预计将在2027年第二季度前完成，相关成本将在同年下半年生效。该公司称，此前公布的临床资产时间表保持不变。
Emerging clinical data for its lead radiotherapeutic drug candidate encouraged company transformation with focus on targeted radiotherapy, CEO Patrick Amstutz said in a statement The reduction is expected be completed by the second quarter of 2027 and the related costs set to come into effect in the second half of the same year, Molecular Partners said Previously announced timelines on clinical assets stand, the company said